or Try an Advanced Search...

    Technical Analysis for PRME - Prime Medicine, Inc.

    Grade Last Price % Change Price Change
    C 4.03 3.87% 0.15
    PRME closed up 3.87 percent on Friday, November 1, 2024, on 33 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Down
    Historical PRME trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    Inside Day Range Contraction 0.00%
    Fell Below 20 DMA Bearish 3.87%
    Fell Below 50 DMA Bearish 3.87%
    Down 3 Days in a Row Weakness 3.87%
    Wide Bands Range Expansion -0.98%
    50 DMA Support Bullish -1.23%
    Wide Bands Range Expansion -1.23%
    180 Bullish Setup Bullish Swing Setup -4.28%
    Older End-of-Day Signals for PRME ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 20 hours ago
    Possible Inside Day about 20 hours ago
    Up 3% about 21 hours ago
    20 DMA Support about 21 hours ago
    Reversed from Up about 22 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    PRME Chart by TradingView
    Basic chart:

    Profile

    Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing, if approved, could offer a one-time curative genetic therapeutic option to a broad set of patients.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Disease Emerging Technologies Molecular Biology Medical Genetics Genetic Engineering Gene Editing Gene Editing Technology

    Is PRME a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 28 12 High-Growth Stocks That Could Deliver Parabolic Returns
    Oct 24 Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
    Oct 16 Why I Keep Buying These 14 Incredible Growth Stocks
    Oct 15 Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
    Oct 1 PRME Stock Rises 11.8% on Collaboration With Bristol Myers
    Oct 1 BMS and Prime ink potential $3.5bn deal to develop T cell therapies
    Sep 30 Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
    Sep 30 Dow Dips 300 Points; Emcore Shares Spike Higher
    Sep 30 Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
    Sep 30 Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
    See more PRME news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 9.86
    52 Week Low 3.28
    Average Volume 1,625,076
    200-Day Moving Average 5.68
    50-Day Moving Average 3.90
    20-Day Moving Average 3.96
    10-Day Moving Average 4.13
    Average True Range 0.31
    RSI (14) 51.46
    ADX 24.6
    +DI 20.97
    -DI 17.37
    Chandelier Exit (Long, 3 ATRs) 3.56
    Chandelier Exit (Short, 3 ATRs) 4.25
    Upper Bollinger Bands 4.49
    Lower Bollinger Band 3.43
    Percent B (%b) 0.57
    BandWidth 26.81
    MACD Line 0.06
    MACD Signal Line 0.06
    MACD Histogram 0.0014
    Fundamentals Value
    Market Cap 392.22 Million
    Num Shares 97.3 Million
    EPS -1.78
    Price-to-Earnings (P/E) Ratio -2.26
    Price-to-Sales 0.00
    Price-to-Book 3.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.33
    Resistance 3 (R3) 4.30 4.18 4.28
    Resistance 2 (R2) 4.18 4.10 4.19 4.26
    Resistance 1 (R1) 4.10 4.05 4.14 4.13 4.25
    Pivot Point 3.98 3.98 4.00 3.99 3.98
    Support 1 (S1) 3.90 3.90 3.94 3.93 3.81
    Support 2 (S2) 3.78 3.85 3.79 3.80
    Support 3 (S3) 3.70 3.78 3.78
    Support 4 (S4) 3.73